- Home
- CAG vs BMRN Comparison
CAG vs BMRN Comparison
Compare CAG & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAG
- BMRN
- Stock Information
- Founded
- CAG 1919
- BMRN 1996
- Country
- CAG United States
- BMRN United States
- Employees
- CAG N/A
- BMRN N/A
- Industry
- CAG Packaged Foods
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CAG Consumer Staples
- BMRN Health Care
- Exchange
- CAG Nasdaq
- BMRN Nasdaq
- Market Cap
- CAG 9.3B
- BMRN 11.1B
- IPO Year
- CAG N/A
- BMRN 1999
- Fundamental
- Price
- CAG $19.18
- BMRN $54.09
- Analyst Decision
- CAG Hold
- BMRN Buy
- Analyst Count
- CAG 11
- BMRN 24
- Target Price
- CAG $21.73
- BMRN $91.70
- AVG Volume (30 Days)
- CAG 11.3M
- BMRN 1.7M
- Earning Date
- CAG 10-01-2025
- BMRN 10-28-2025
- Dividend Yield
- CAG 7.30%
- BMRN N/A
- EPS Growth
- CAG 233.33
- BMRN 154.69
- EPS
- CAG 2.40
- BMRN 3.40
- Revenue
- CAG $11,612,800,000.00
- BMRN $3,063,608,000.00
- Revenue This Year
- CAG N/A
- BMRN $13.32
- Revenue Next Year
- CAG N/A
- BMRN $9.37
- P/E Ratio
- CAG $7.99
- BMRN $15.91
- Revenue Growth
- CAG N/A
- BMRN 18.36
- 52 Week Low
- CAG $18.19
- BMRN $52.93
- 52 Week High
- CAG $33.04
- BMRN $85.00
- Technical
- Relative Strength Index (RSI)
- CAG 48.50
- BMRN 37.63
- Support Level
- CAG $19.03
- BMRN $55.99
- Resistance Level
- CAG $19.59
- BMRN $59.79
- Average True Range (ATR)
- CAG 0.43
- BMRN 1.57
- MACD
- CAG 0.05
- BMRN -0.40
- Stochastic Oscillator
- CAG 57.52
- BMRN 0.70
About CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.